Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults with Stage III or IV Classical Hodgkin Lymphoma in ECHELON-1

Overview

Journal Haematologica

Specialty Hematology

Date 2023 Oct 5

PMID 37794803

Authors

Howland E Crosswell

Ann S LaCasce

Nancy L Bartlett

David J Straus

Kerry J Savage

Pier Luigi Zinzani

Graham P Collins

Michelle Fanale

Keenan Fenton

Cassie Dong

Harry Miao

Andrew P Grigg

Affiliations

Soon will be listed here.

Citing Articles

Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations.

Aldoughaim M, Alsuhebany N, Alzahrani M, Alqahtani T, Alghamdi S, Badreldin H Clin Med Insights Oncol. 2024; 18:11795549241298541.

PMID: 39559827 PMC: 11571259. DOI: 10.1177/11795549241298541.

References

Radford J, Eardley A, Woodman C, Crowther D . Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997; 314(7077):343-6. PMC: 2125852. DOI: 10.1136/bmj.314.7077.343a. View

Connors J, Jurczak W, Straus D, Ansell S, Kim W, Gallamini A . Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2017; 378(4):331-344. PMC: 5819601. DOI: 10.1056/NEJMoa1708984. View

Stephens D, Li H, Schoder H, Straus D, Moskowitz C, LeBlanc M . Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019; 134(15):1238-1246. PMC: 6788007. DOI: 10.1182/blood.2019000719. View

Aben K, van Gaal C, van Gils N, van der Graaf W, Zielhuis G . Cancer in adolescents and young adults (15-29 years): a population-based study in the Netherlands 1989-2009. Acta Oncol. 2012; 51(7):922-33. DOI: 10.3109/0284186X.2012.705891. View

Ansell S, Radford J, Connors J, Dlugosz-Danecka M, Kim W, Gallamini A . Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022; 387(4):310-320. DOI: 10.1056/NEJMoa2206125. View

Straus D, Collins G, Walewski J, Zinzani P, Grigg A, Sureda A . Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma. 2020; 61(12):2931-2938. DOI: 10.1080/10428194.2020.1791846. View

Rodday A, Parsons S, Upshaw J, Friedberg J, Gallamini A, Hawkes E . The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. J Clin Oncol. 2022; 41(11):2076-2086. PMC: 10082254. DOI: 10.1200/JCO.22.02473. View

Metzger M, Link M, Billett A, Flerlage J, Lucas Jr J, Mandrell B . Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. J Clin Oncol. 2021; 39(20):2276-2283. PMC: 8260923. DOI: 10.1200/JCO.20.03286. View

Castellino S, Pei Q, Parsons S, Hodgson D, McCarten K, Horton T . Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022; 387(18):1649-1660. PMC: 9945772. DOI: 10.1056/NEJMoa2206660. View

10.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D . PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017; 390(10114):2790-2802. DOI: 10.1016/S0140-6736(17)32134-7. View

11.

Xavier A, Epperla N, Taub J, Costa L . Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. Am J Hematol. 2017; 93(2):238-245. PMC: 6863150. DOI: 10.1002/ajh.24964. View

12.

Hapgood G, Zheng Y, Sehn L, Villa D, Klasa R, Gerrie A . Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. J Clin Oncol. 2016; 34(21):2493-500. DOI: 10.1200/JCO.2015.65.4194. View